Dr. Myriam Chalabi

Young Investigator - International

Myriam Chalabi was born in Tripoli, Lebanon. When she was 5 years old, she moved with her family to the island of Curacao. After graduating from high school in 2002, she moved to the Netherlands to study medicine. She graduated from Medical School in 2008 and subsequently did her residency in internal medicine/medical oncology. In 2016 she became staff member at the Netherlands Cancer Institute in Amsterdam in the department of gastrointestinal oncology. She currently holds the role of clinician-scientist and clinical group leader. Myriam is the lead investigator (PI) of several investigator-initiated neoadjuvant immunotherapy trials in gastrointestinal cancers. This includes the globally renowned NICHE-2 study, in which patients with mismatch-repair deficient/microsatellite instability high colon cancers were found to have impressive responses after a short duration of neoadjuvant immunotherapy, leading to implementation of this treatment, including regulatory approvals, in various countries and the inclusion in guidelines. Her work with neoadjuvant immunotherapy in mismatch-repair proficient colon cancers has recently led to two large randomized international studies, in which she plays a key role. 
Her work also includes immunotherapy trials across tumor types (pan-cancer NEOASIS study), in addition to gastrointestinal cancers. Another main focus of her research is the correlative translational research, with which her group aims to better understand the drivers of response in mismatch-repair-proficient and -deficient tumors and develop rationale for novel immunotherapy combinations.
In 2022 she was named one of the 11 early career researchers to watch by Nature Medicine. In 2026, she was awarded the prestigious Takeda and Nature Innovators in Science Award.